Type I interferons in Sjögren's syndrome

Autoimmunity Reviews

Volumn 12, Issue 5, 2013, Pages 558-566

  Yao, Yihong ^a   Liu, Zheng ^a   Jallal, Bahija ^a   Shen, Nan ^b   Rönnblom, Lars ^c  

^a MEDIMMUNE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AGS; Autoimmune; FDC; IDC; Microarray; MSG; NK; PBMC; PDC; Plasmacytoid dendritic cell; PSjS; SGEC; Sj gren's syndrome; SLE; Treg; Type I IFN; Type I interferon

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; ETANERCEPT; INTERFERON; LA ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN; MICRORNA; RO ANTIBODY; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; VIRUS RNA;

APOPTOSIS; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CELL ACTIVATION; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENTEROVIRUS; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; GENE MUTATION; HEPATITIS C VIRUS; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; INCIDENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; RNA INTERFERENCE; SALIVARY GLAND BIOPSY; SERUM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VIRUS INFECTION; VIRUS STRAIN;

HUMANS; INTERFERON TYPE I; SJOGREN'S SYNDROME;

EID: 84875249373     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.10.006     Document Type: Review

References (140)

1. Sjogren H. On knowledge of kerataconjunctivitis sicca. Keratitis filiformis due to lacrimal gland hypofunction. Acta Opthalmol 1933, (Suppl. 2):1-151.
2. Papiris S.A., Maniati M., Constantopoulos S.H., Roussos C., Moutsopoulos H.M., Skopouli F.N. Lung involvement in primary Sjogren's syndrome is mainly related to the small airway disease. Ann Rheum Dis 1999, 58:61-64.
3. Tu W.H., Shearn M.A., Lee J.C., Hopper J. Interstitial nephritis in Sjogren's syndrome. Ann Intern Med 1968, 69:1163-1170.
4. Skopouli F.N., Barbatis C., Moutsopoulos H.M. Liver involvement in primary Sjogren's syndrome. Br J Rheumatol 1994, 33:745-748.
5. Fox R.I. Sjogren's syndrome. Lancet 2005, 366:321-331.
6. Kapadia M., Sakic B. Autoimmune and inflammatory mechanisms of CNS damage. Prog Neurobiol 2011, 95:301-333.
7. Skopouli F.N., Dafni U., Ioannidis J.P., Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 2000, 29:296-304.
8. Voulgarelis M., Dafni U.G., Isenberg D.A., Moutsopoulos H.M. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 1999, 42:1765-1772.
9. Tzioufas A.G., Boumba D.S., Skopouli F.N., Moutsopoulos H.M. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 1996, 39:767-772.
10. Iaccarino L., Gatto M., Bettio S., Caso F., Rampudda M., Zen M., et al. Overlap connective tissue disease syndromes. Autoimmun Rev 2013, 12:363-373.
11. Alamanos Y., Tsifetaki N., Voulgari P.V., Venetsanopoulou A.I., Siozos C., Drosos A.A. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) 2006, 45:187-191.
12. Trontzas P.I., Andrianakos A.A. Sjogren's syndrome: a population based study of prevalence in Greece. The ESORDIG study. Ann Rheum Dis 2005, 64:1240-1241.
13. Bowman S.J., Ibrahim G.H., Holmes G., Hamburger J., Ainsworth J.R. Estimating the prevalence among Caucasian women of primary Sjogren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 2004, 33:39-43.
14. Delaleu N., Jonsson M.V., Appel S., Jonsson R. New concepts in the pathogenesis of Sjogren's syndrome. Rheum Dis Clin North Am 2008, 34:833-845. [vii].
15. Jonsson R., Bolstad A.I., Brokstad K.A., Brun J.G. Sjogren's syndrome-a plethora of clinical and immunological phenotypes with a complex genetic background. Ann N Y Acad Sci 2007, 1108:433-447.
16. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos H.M. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun 2010, 34:400-407.
17. Lee B.H., Tudares M.A., Nguyen C.Q. Sjogren's syndrome: an old tale with a new twist. Arch Immunol Ther Exp (Warsz) 2009, 57:57-66.
18. Lane H.C., Callihan T.R., Jaffe E.S., Fauci A.S., Moutsopoulos H.M. Presence of intracytoplasmic IgG in the lymphocytic infiltrates of the minor salivary glands of patients with primary Sjogren's syndrome. Clin Exp Rheumatol 1983, 1:237-239.
19. Varin M.M., Guerrier T., Devauchelle-Pensec V., Jamin C., Youinou P., Pers J.O. In Sjogren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun Rev 2012, 11:252-258.
20. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
21. Op De Beeck K., Vermeersch P., Verschueren P., Westhovens R., Marien G., Blockmans D., et al. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev 2011, 10:801-808.
22. Op De Beeck K., Vermeersch P., Verschueren P., Westhovens R., Marien G., Blockmans D., et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev 2012, 12:137-143.
23. Iaccarino L., Ghirardello A., Canova M., Zen M., Bettio S., Nalotto L., et al. Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. Autoimmun Rev 2011, 10:553-558.
24. Ghillani P., Andre C., Toly C., Rouquette A.M., Bengoufa D., Nicaise P., et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev 2011, 10:509-513.
25. Racanelli V., Prete M., Musaraj G., Dammacco F., Perosa F. Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev 2011, 10:503-508.
26. Xanthou G., Polihronis M., Tzioufas A.G., Paikos S., Sideras P., Moutsopoulos H.M. "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjogren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum 2001, 44:408-418.
27. Tsunawaki S., Nakamura S., Ohyama Y., Sasaki M., Ikebe-Hiroki A., Hiraki A., et al. Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjogren's syndrome. J Rheumatol 2002, 29:1884-1896.
28. Dimitriou I.D., Kapsogeorgou E.K., Moutsopoulos H.M., Manoussakis M.N. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjogren's syndrome patients indicating their intrinsic activation. Clin Exp Immunol 2002, 127:386-392.
29. Lavie F., Miceli-Richard C., Quillard J., Roux S., Leclerc P., Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 2004, 202:496-502.
30. Ohlsson M., Szodoray P., Loro L.L., Johannessen A.C., Jonsson R. CD40, CD154, Bax and Bcl-2 expression in Sjogren's syndrome salivary glands: a putative anti-apoptotic role during its effector phases. Scand J Immunol 2002, 56:561-571.
31. Shim G.J., Warner M., Kim H.J., Andersson S., Liu L., Ekman J., et al. Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc Natl Acad Sci U S A 2004, 101:12628-12633.
32. Ishimaru N., Arakaki R., Yoshida S., Yamada A., Noji S., Hayashi Y. Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjogren's syndrome-like autoimmune exocrinopathy. J Exp Med 2008, 205:2915-2927.
33. Lee T.P., Chiang B.L. Sex differences in spontaneous versus induced animal models of autoimmunity. Autoimmun Rev 2012, 11:A422-A429.
34. Shelly S., Boaz M., Orbach H. Prolactin and autoimmunity. Autoimmun Rev 2012, 11:A465-A470.
35. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336.
36. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005, 5:375-386.
37. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007, 6:975-990.
38. Ronnblom L., Alm G.V. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001, 194:F59-F63.
39. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835-1837.
40. Kirou K.A., Mavragani C.P., Crow M.K. Activation of type I interferon in systemic lupus erythematosus. Expert Rev Clin Immunol 2007, 3:579-588.
41. Walsh R.J., Kong S.W., Yao Y., Jallal B., Kiener P.A., Pinkus J.L., et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007, 56:3784-3792.
42. Greenberg S.A., Pinkus J.L., Pinkus G.S., Burleson T., Sanoudou D., Tawil R., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57:664-678.
43. Bave U., Nordmark G., Lovgren T., Ronnelid J., Cajander S., Eloranta M.L., et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005, 52:1185-1195.
44. Hjelmervik T.O., Petersen K., Jonassen I., Jonsson R., Bolstad A.I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005, 52:1534-1544.
45. Higgs B.W., Liu Z., White B., Zhu W., White W.I., Morehouse C., et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011, 70:2029-2036.
46. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723.
47. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100:2610-2615.
48. van der Pouw Kraan T.C., Wijbrandts C.A., van Baarsen L.G., Voskuyl A.E., Rustenburg F., Baggen J.M., et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007, 66:1008-1014.
49. Wong D., Kea B., Pesich R., Higgs B.W., Zhu W., Brown P., et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One 2012, 7:e29161.
50. Zheng L., Zhang Z., Yu C., Tu L., Zhong L., Yang C. Association between IFN-alpha and primary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 107:e12-e18.
51. Bolstad A.I., Jonsson R. Genetic aspects of Sjogren's syndrome. Arthritis Res 2002, 4:353-359.
52. Nepom G.T. MHC and autoimmune diseases. Immunol Ser 1993, 59:143-164.
53. Merriman T.R., Todd J.A. Genetics of autoimmune disease. Curr Opin Immunol 1995, 7:786-792.
54. Tomlinson I.P., Bodmer W.F. The HLA system and the analysis of multifactorial genetic disease. Trends Genet 1995, 11:493-498.
55. Cruz-Tapias P., Rojas-Villarraga A., Maier-Moore S., Anaya J.M. HLA and Sjogren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 2012, 11:281-287.
56. Baechler E.C., Batliwalla F.M., Reed A.M., Peterson E.J., Gaffney P.M., Moser K.L., et al. Gene expression profiling in human autoimmunity. Immunol Rev 2006, 210:120-137.
57. Barnes B.J., Moore P.A., Pitha P.M. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001, 276:23382-23390.
58. Barnes B.J., Richards J., Mancl M., Hanash S., Beretta L., Pitha P.M. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 2004, 279:45194-45207.
59. Graham R.R., Kyogoku C., Sigurdsson S., Vlasova I.A., Davies L.R., Baechler E.C., et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 2007, 104:6758-6763.
60. Sigurdsson S., Goring H.H., Kristjansdottir G., Milani L., Nordmark G., Sandling J.K., et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008, 17:872-881.
61. Miceli-Richard C., Comets E., Loiseau P., Puechal X., Hachulla E., Mariette X. Association of an IRF5 gene functional polymorphism with Sjogren's syndrome. Arthritis Rheum 2007, 56:3989-3994.
62. Miceli-Richard C., Gestermann N., Ittah M., Comets E., Loiseau P., Puechal X., et al. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjogren's syndrome. Arthritis Rheum 2009, 60:1991-1997.
63. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376.
64. Nordmark G., Alm G.V., Ronnblom L. Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2006, 2:262-269.
65. Triantafyllopoulou A., Moutsopoulos H. Persistent viral infection in primary Sjogren's syndrome: review and perspectives. Clin Rev Allergy Immunol 2007, 32:210-214.
66. Saito I., Servenius B., Compton T., Fox R.I. Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome. J Exp Med 1989, 169:2191-2198.
67. Mariette X., Gozlan J., Clerc D., Bisson M., Morinet F. Detection of Epstein-Barr virus DNA by in situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjogren's syndrome. Am J Med 1991, 90:286-294.
68. Nagata Y., Inoue H., Yamada K., Higashiyama H., Mishima K., Kizu Y., et al. Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients. Immunology 2004, 111:223-229.
69. Yamaoka K., Miyasaka N., Yamamoto K. Possible involvement of Epstein-Barr virus in polyclonal B cell activation in Sjogren's syndrome. Arthritis Rheum 1988, 31:1014-1021.
70. Yao Y., Higgs B.W., Morehouse C., de Los Reyes M., Trigona W., Brohawn P., et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genom Proteomics 2009, 1-16. [2009].
71. Yao Y., Higgs B.W., Richman L., White B., Jallal B. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res Ther 2010, 12(Suppl. 1):S6.
72. Niewold T.B., Rivera T.L., Buyon J.P., Crow M.K. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum 2008, 58:541-546.
73. Mavragani C.P., Niewold T.B., Moutsopoulos N.M., Pillemer S.R., Wahl S.M., Crow M.K. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 2007, 56:3995-4004.
74. Tannous B.A., Kim D.E., Fernandez J.L., Weissleder R., Breakefield X.O. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 2005, 11:435-443.
75. Higgs B.W., Liu Z., Zhu W., White W.I., Richman L., Jallal B., et al. Type I interferon in rheumatoid arthritis, systemic lupus erythematosus, myositis and systemic scleroderma-a review of transcript profiling studies in the blood. Eur Musculoskeletal Rev 2012, 7:22-28.
76. Yao Y., Richman L., Morehouse C., de los Reyes M., Higgs B.W., Boutrin A., et al. Type I interferon: potential therapeutic target for psoriasis?. PLoS One 2008, 3:e2737.
77. Der S.D., Zhou A., Williams B.R., Silverman R.H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998, 95:15623-15628.
78. Tan F.K., Zhou X., Mayes M.D., Gourh P., Guo X., Marcum C., et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006, 45:694-702.
79. Wildenberg M.E., van Helden-Meeuwsen C.G., van de Merwe J.P., Drexhage H.A., Versnel M.A. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008, 38:2024-2033.
80. Nzeusseu Toukap A., Galant C., Theate I., Maudoux A.L., Lories R.J., Houssiau F.A., et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 2007, 56:1579-1588.
81. Yao Y., Richman L., Higgs B.W., Morehouse C.A., de los Reyes M., Brohawn P., et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1785-1796.
82. Fleming J.N., Nash R.A., McLeod D.O., Fiorentino D.F., Shulman H.M., Connolly M.K., et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?. PLoS One 2008, 3:e1452.
83. Coelho L.F., de Oliveira J.G., de Oliveira D.B., Guedes A.C., Lanna C.C., Prados R.Z., et al. Increased expression of 2'5'oligoadenylate synthetase and double-stranded RNA dependent protein kinase messenger RNAs on affected skin of systemic sclerosis patients. Arch Dermatol Res 2007, 299:259-262.
84. Greenberg S.A., Higgs B.W., Morehouse C., Walsh R.J., Won Kong S., Brohawn P., et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 2011, 13:207-213.
85. Baechler E.C., Bauer J.W., Slattery C.A., Ortmann W.A., Espe K.J., Novitzke J., et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007, 13:59-68.
86. Eloranta M.L., Franck-Larsson K., Lovgren T., Kalamajski S., Ronnblom A., Rubin K., et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010, 69:1396-1402.
87. Gottenberg J.E., Cagnard N., Lucchesi C., Letourneur F., Mistou S., Lazure T., et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci U S A 2006, 103:2770-2775.
88. Ittah M., Miceli-Richard C., Eric Gottenberg J., Lavie F., Lazure T., Ba N., et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006, 8:R51.
89. Emamian E.S., Leon J.M., Lessard C.J., Grandits M., Baechler E.C., Gaffney P.M., et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009, 10:285-296.
90. Farkas L., Beiske K., Lund-Johansen F., Brandtzaeg P., Jahnsen F.L. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001, 159:237-243.
91. Lande R., Gafa V., Serafini B., Giacomini E., Visconti A., Remoli M.E., et al. Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-beta. J Neuropathol Exp Neurol 2008, 67:388-401.
92. Blomberg S., Eloranta M.L., Cederblad B., Nordlin K., Alm G.V., Ronnblom L. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001, 10:484-490.
93. van Holten J., Smeets T.J., Blankert P., Tak P.P. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis 2005, 64:1780-1782.
94. Van Krinks C.H., Matyszak M.K., Gaston J.S. Characterization of plasmacytoid dendritic cells in inflammatory arthritis synovial fluid. Rheumatology (Oxford) 2004, 43:453-460.
95. Greenberg S.A. A gene expression approach to study perturbed pathways in myositis. Curr Opin Rheumatol 2007, 19:536-541.
96. Wenzel J., Schmidt R., Proelss J., Zahn S., Bieber T., Tuting T. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 2006, 31:576-582.
97. Cederblad B., Blomberg S., Vallin H., Perers A., Alm G.V., Ronnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha- producing cells. J Autoimmun 1998, 11:465-470.
98. Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543.
99. Vogelsang P., Brun J.G., Oijordsbakken G., Skarstein K., Jonsson R., Appel S. Levels of plasmacytoid dendritic cells and type-2 myeloid dendritic cells are reduced in peripheral blood of patients with primary Sjogren's syndrome. Ann Rheum Dis 2010, 69:1235-1238.
100. Guellec D., Cornec D., Jousse-Joulin S., Marhadour T., Marcorelles P., Pers J.O., et al. Diagnostic value of labial minor salivary gland biopsy for Sjogren's syndrome: a systematic review. Autoimmun Rev 2013, 12:416-420.
101. Deshmukh U.S., Nandula S.R., Thimmalapura P.R., Scindia Y.M., Bagavant H. Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med 2009, 38:42-47.
102. Spachidou M.P., Bourazopoulou E., Maratheftis C.I., Kapsogeorgou E.K., Moutsopoulos H.M., Tzioufas A.G., et al. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren's syndrome. Clin Exp Immunol 2007, 147:497-503.
103. Bave U., Alm G.V., Ronnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol 2000, 165:3519-3526.
104. Lovgren T., Eloranta M.L., Kastner B., Wahren-Herlenius M., Alm G.V., Ronnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006, 54:1917-1927.
105. Strandberg L., Ambrosi A., Espinosa A., Ottosson L., Eloranta M.L., Zhou W., et al. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol 2008, 28:220-231.
106. Krapf F.E., Herrmann M., Leitmann W., Kalden J.R. Are retroviruses involved in the pathogenesis of SLE? Evidence demonstrated by molecular analysis of nucleic acids from SLE patients' plasma. Rheumatol Int 1989, 9:115-121.
107. Li J.Z., Steinman C.R. Plasma DNA in systemic lupus erythematosus. Characterization of cloned base sequences. Arthritis Rheum 1989, 32:726-733.
108. Steinman C.R. Circulating DNA in systemic lupus erythematosus. Isolation and characterization. J Clin Invest 1984, 73:832-841.
109. Mavragani C.P., Crow M.K. Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun 2010, 35:225-231.
110. Mavragani C.P., Kapsogeorgou E.K., Pierce D., Seshan S., Moutsopoulos H., Crow M.K. Endogenous LINE-1 (L1) retrotransposon elements: candidate triggers of Type I Interferon (IFN) production in autoimmune disorders. Arthritis Rheum 2007, 56:S630.
111. Pascual V., Banchereau J. Tracking interferon in autoimmunity. Immunity 2012, 36:7-9.
112. Bhoj V.G., Chen Z.J. Linking retroelements to autoimmunity. Cell 2008, 134:569-571.
113. Stetson D.B., Ko J.S., Heidmann T., Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587-598.
114. Crow Y.J., Hayward B.E., Parmar R., Robins P., Leitch A., Ali M., et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet 2006, 38:917-920.
115. Lee-Kirsch M.A., Gong M., Chowdhury D., Senenko L., Engel K., Lee Y.A., et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007, 39:1065-1067.
116. Kavanagh D., Spitzer D., Kothari P.H., Shaikh A., Liszewski M.K., Richards A., et al. New roles for the major human 3'-5' exonuclease TREX1 in human disease. Cell Cycle 2008, 7:1718-1725.
117. Stetson D.B., Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 2006, 24:93-103.
118. Martin D.A., Elkon K.B. Intracellular mammalian DNA stimulates myeloid dendritic cells to produce type I interferons predominantly through a toll-like receptor 9-independent pathway. Arthritis Rheum 2006, 54:951-962.
119. Okabe Y., Kawane K., Akira S., Taniguchi T., Nagata S. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med 2005, 202:1333-1339.
120. Villanueva E., Yalavarthi S., Berthier C.C., Hodgin J.B., Khandpur R., Lin A.M., et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011, 187:538-552.
121. Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra19.
122. Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra20.
123. Bosch X. Systemic lupus erythematosus and the neutrophil. N Engl J Med 2011, 365:758-760.
124. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
125. Fuchs T.A., Abed U., Goosmann C., Hurwitz R., Schulze I., Wahn V., et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007, 176:231-241.
126. Lu Q., Renaudineau Y., Cha S., Ilei G., Brooks W.H., Selmi C., et al. Epigenetics in autoimmune disorders: highlights of the 10th Sjogren's syndrome symposium. Autoimmun Rev 2010, 9:627-630.
127. Richardson B., Scheinbart L., Strahler J., Gross L., Hanash S., Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990, 33:1665-1673.
128. Garaud S., Le Dantec C., Jousse-Joulin S., Hanrotel-Saliou C., Saraux A., Mageed R.A., et al. IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J Immunol 2009, 182:5623-5632.
129. Zhao S., Long H., Lu Q. Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers, and therapeutic potentials. Clin Rev Allergy Immunol 2010, 39:3-9.
130. Trenkmann M., Brock M., Ospelt C., Gay S. Epigenetics in rheumatoid arthritis. Clin Rev Allergy Immunol 2010, 39:10-19.
131. Deng C., Lu Q., Zhang Z., Rao T., Attwood J., Yung R., et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003, 48:746-756.
132. Fukuda-Kamitani T., Kamitani T. Ubiquitination of Ro52 autoantigen. Biochem Biophys Res Commun 2002, 295:774-778.
133. Terzoglou A.G., Routsias J.G., Avrameas S., Moutsopoulos H.M., Tzioufas A.G. Preferential recognition of the phosphorylated major linear B-cell epitope of La/SSB 349-368 aa by anti-La/SSB autoantibodies from patients with systemic autoimmune diseases. Clin Exp Immunol 2006, 144:432-439.
134. Mavragani C.P., Moffit K., Kapsogeorgou E.K., Moutsopoulos H., Crow M.K. Coordinate expression of defensive regulators of L1 endogenous retroelements in primary Sjogren's syndrome. Arthritis Rheum 2007, 56:S542.
135. Chua J.H., Armugam A., Jeyaseelan K. MicroRNAs: biogenesis, function and applications. Curr Opin Mol Ther 2009, 11:189-199.
136. Liston A., Linterman M., Lu L.F. MicroRNA in the adaptive immune system, in sickness and in health. J Clin Immunol 2010, 30:339-346.
137. Nakasa T., Miyaki S., Okubo A., Hashimoto M., Nishida K., Ochi M., et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 2008, 58:1284-1292.
138. Tang Y., Luo X., Cui H., Ni X., Yuan M., Guo Y., et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009, 60:1065-1075.
139. Pauley K.M., Stewart C.M., Gauna A.E., Dupre L.C., Kuklani R., Chan A.L., et al. Altered miR-146a expression in Sjogren's syndrome and its functional role in innate immunity. Eur J Immunol 2011, 41:2029-2039.
140. McBride J.M., Wallace D.J., Yao Z., Morimoto A., Jiang J., Maciuca R., et al. Dose-dependent modulation of interferon regulated genes with administration of single and repeat doses of Rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE [abstract]. Arthritis Rheum 2009, 60:S775.